
Scrip Podcasts
Listen to Scrip podcasts for our perspectives on biopharma R&D, deal-making, product strategies and other key commercial topics.

Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.

Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: BMS’s new products meet early expectations; Eisai to shut a US unit in global R&D restructuring; Roche aims high for Vabysmo; US priority review for Biogen’s ALS contender; and a chat with Gennova’s CEO.

CEO Of India's mRNA Pioneer Gennova On Cancer Vaccines, VC Interest
Founder CEO Sanjay Singh tells Scrip about Gennova Biopharma's preliminary talks with investors looking to grab a piece of the action post approval of its mRNA vaccine against COVID-19. As the company considers use of the technology in making vaccines against cancer and infectious diseases, it will also expand manufacturing

Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: Novo obesity drugs in US cost-effectiveness spotlight; Biogen’s growth challenges; Novartis’s view on large M&A; pharma’s Q2 outlook; and MSD on Lagevrio.

Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: setback for a COVID-19 candidate; Chinese biotechs move into mRNA; Sanofi’s strategic moves into hemophilia; Orion’s deal for its novel prostate cancer candidate; and Roche’s evolving approach to platform deals.

New Chinese-Language Podcast: 聊聊生物制药热门话题
Join our China-based content team for this inaugural Chinese-language podcast discussing selected recent hot topics impacting the biopharma industry in China, including bispecific antibodies, antibody-drug conjugates and new regulatory policies designed to speed product approvals.

Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: a look a top executive compensation; BioMarin preps for Roctavian’s EU debut; Argenx eyes launch hat-trick for Vyvgart; is a biopharma M&A wave coming; and J&J’s Gorsky offers leadership lessons.

It’s Coming Home: ImmunoACT Advances Plans For Cut-Price CAR-T In India
ImmunoACT CEO Dr Rahul Purwar outlines progress made by the firm’s early-stage CAR-T therapy in India, which he believes can be available at a tenth of the price of current on-market treatments or around the cost range for bone marrow transplant. Laurus Labs, which holds about 27% in ImmunoACT, is expected to help shape the firm’s globalization plans.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.